Welcome to CDC stacks |
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Filetype[PDF-25.30 MB]


This document cannot be previewed automatically as it exceeds 5 MB
Please click the thumbnail image to view the document.
Prevention and control of meningococcal disease : recommendations of the Advisory Committee on Immunization Practices (ACIP)
Details:
  • Supporting Files:
    No Additional Files
This document has replaced (most recent first):
  1. Prevention and control of meningococcal disease : recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Personal Author:
    Rosenstein, Nancy E.; Perkins, Bradley A.;
    Corporate Authors:
    United States. Advisory Committee on Immunization Practices.. National Center for Infectious Diseases (U.S.). Division of Bacterial and Mycotic Diseases..
    Published Date:
    June 30, 2000
    Source:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 2000; 49(RR-7):1-10.
    Description:
    This report summarizes and updates an earlier published statement issued by the Advisory Committee on Immunization Practices concerning the control and prevention of meningococcal disease (MMWR 1997:46[No. RR-5]:1-21) and provides updated recommendat...
    Status:
    superseded
    File Type:
    Filetype[PDF - 179.37 KB]
  2. Revised recommendations of the Advisory Committee on Immunization Practices to Vaccinate all Persons Aged 11-18 Years with Meningococcal Conjugate Vaccine
    Corporate Authors:
    United States. Advisory Committee on Immunization Practices.
    Published Date:
    August 10, 2007
    Source:
    MMWR. Morbidity and mortality weekly report. 2007; 56(31):794-5.
    Description:
    In January 2005, a quadrivalent meningococcal polysaccharide- protein conjugate vaccine (MCV4) (Menactra™, Sanofi Pasteur, Inc., Swiftwater, Pennsylvania) was licensed for use among persons aged 11–55 years. In May 2005, the Advisory Committee on...
    Status:
    superseded
    File Type:
    Filetype[PDF - 515.21 KB]
  3. Prevention and control of meningococcal disease : recommendations of the Advisory Committee on Immunization Practices (ACIP)
    Personal Author:
    Bilukha, Oleg; Rosenstein, Nancy E.;
    Corporate Authors:
    United States. Advisory Committee on Immunization Practices.. Centers for Disease Control and Prevention (U.S.). National Center for Infectious Diseases (U.S.). Division of Bacterial and Mycotic Diseases..
    Published Date:
    May 27, 2005
    Series:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 49, no. RR-7
    Description:
    "In January 2005, a tetravalent meningococcal polysaccharide-protein conjugate vaccine ([MCV4] Menactra, manufactured by Sanofi Pasteur, Inc., Swiftwater, Pennsylvania) was licensed for use among persons aged 11-55 years. CDCns Advisory Committee on ...
    Status:
    superseded
    File Type:
    Filetype[PDF - 321.91 KB]
  4. Recommendation of the Advisory Committee on Immunization Practices (ACIP) for Use of Quadrivalent Meningococcal Conjugate Vaccine (MenACWY-D) Among Children Aged 9 Through 23 Months at Increased Risk for Invasive Meningococcal Disease. MMWR 60 (40): 1391-1392.
    Corporate Authors:
    United States. Advisory Committee on Immunization Practices.
    Published Date:
    October 14, 2011
    Source:
    MMWR. Morbidity and mortality weekly report. 2011; 60(40):1391-2.
    Description:
    In April 2011, the Food and Drug Administration approved the use of a quadrivalent meningococcal conjugate vaccine (MenACWY-D) (Menactra, Sanofi Pasteur) as a 2-dose primary series among children aged 9 through 23 months (1). Vaccination with meningo...
    Status:
    superseded
    File Type:
    Filetype[PDF - 64.63 KB]
  5. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease
    Corporate Authors:
    United States. Advisory Committee on Immunization Practices.
    Published Date:
    September 25, 2009
    Source:
    MMWR. Morbidity and mortality weekly report. 2009; 58(37):1042-3.
    Description:
    The Advisory Committee on Immunization Practices (ACIP) recommends quadrivalent meningococcal conjugate vaccine, (MCV4) (Menactra, Sanofi Pasteur, Swiftwater, Pennsylvania) for all persons aged 11-18 years and for persons aged 2-55 years at increased...
    Status:
    superseded
    File Type:
    Filetype[PDF - 1.49 MB]
  6. Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease--Advisory Committee on Immunization Practices (ACIP), 2011
    Corporate Authors:
    United States. Advisory Committee on Immunization Practices.
    Published Date:
    August 11, 2011
    Source:
    MMWR. Morbidity and mortality weekly report. 2011; 60(30):1018-9.
    Description:
    In January 2011, the Food and Drug Administration lowered the approval age range for use of MenACWY-CRM (Menveo, Novartis Vaccines and Diagnostics), a quadrivalent meningococcal conjugate vaccine, to include persons aged 2 through 55 years. One other...
    Status:
    superseded
    File Type:
    Filetype[PDF - 72.15 KB]
  7. Control and prevention of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Corporate Authors:
    United States. Advisory Committee on Immunization Practices.
    Published Date:
    February 14, 1997
    Source:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 1997; 46(RR-5):1-10.
    Description:
    These recommendations update information regarding the polysaccharide vaccine licensed in the United States for use against disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135, as well as antimicrobial agents for chemoprophylaxis a...
    Status:
    superseded
    File Type:
    Filetype[HTML]
  8. Meningococcal disease and college students : recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Personal Author:
    Rosenstein, Nancy E.; Perkins, Bradley A.;
    Corporate Authors:
    United States. Advisory Committee on Immunization Practices.. National Center for Infectious Diseases (U.S.). Division of Bacterial and Mycotic Diseases..
    Published Date:
    June 30, 2000
    Source:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 2000; 49(RR-7):13-20.
    Description:
    This report provides information regarding the modestly increased risk for meningococcal disease among college freshmen, particularly those who live in dormitories or residence halls. It presents recommendations developed by the Advisory Committee on...
    Status:
    superseded
    File Type:
    Filetype[PDF - 179.37 KB]
  9. Report from the Advisory Committee on Immunization Practices (ACIP) : Decision not to recommend routine vaccination of all children aged 2-10 years with quadrivalent meningococcal conjugate vaccine (MCV4)
    Published Date:
    May 2, 2008
    Source:
    MMWR. Morbidity and mortality weekly report. 2008; 57(17):462-5.
    Description:
    At its February 2008 meeting, the Advisory Committee on Immunization Practices (ACIP) decided not to recommend routine vaccination of children aged 2--10 years against meningococcal disease unless the child is at increased risk for the disease. This ...
    Status:
    superseded
    File Type:
    Filetype[HTML]
  10. Updated Recommendations for Use of Meningococcal Conjugate Vaccines -- Advisory Committee on Immunization Practices (ACIP), 2010
    Corporate Authors:
    United States. Advisory Committee on Immunization Practices.
    Published Date:
    January 28, 2011
    Source:
    MMWR. Morbidity and mortality weekly report. 2011; 60(3):72-6.
    Description:
    On October 27, 2010, the Advisory Committee on Immunization Practices (ACIP) approved updated recommendations for the use of quadrivalent (serogroups A, C, Y, and W-135) meningococcal conjugate vaccines (Menveo, Novartis; and Menactra, Sanofi Pasteur...
    Status:
    superseded
    File Type:
    Filetype[HTML]
  11. Control and prevention of serogroup C meningococcal disease : evaluation and management of suspected outbreaks: recommendations of the Advisory Committee on Immunization Practices (ACIP)
    Corporate Authors:
    United States. Advisory Committee on Immunization Practices.
    Published Date:
    February 14, 1997
    Source:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 1997; 46(RR-5):13-21.
    Description:
    Outbreaks of serogroup C meningococcal disease (SCMD) have been occurring more frequently in the United States since the early 1990s, and the use of vaccine to control these outbreaks has increased. These outbreaks are characterized by increased rate...
    Status:
    superseded
    File Type:
    Filetype[HTML]
  12. Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010.
    Corporate Authors:
    United States. Advisory Committee on Immunization Practices.
    Published Date:
    March 12, 2010
    Source:
    MMWR. Morbidity and mortality weekly report. 2010; 59(9):273.
    Description:
    On February 19, 2010, the Food and Drug Administration (FDA) licensed a quadrivalent meningococcal conjugate vaccine, MenACWY-CRM (Menveo, Novartis Vaccines and Diagnostics). MenACWY-CRM is licensed as a single dose for use among persons aged 11-55 y...
    Status:
    superseded
    File Type:
    Filetype[PDF - 1.59 MB]
You May Also Like:
  1. Weekly cases of notifiable diseases, United States, U.S. territories, and Non-U.S. Residents weeks ending October 17, 2020 (Week 42) Table1w Meningococcal disease
    Corporate Authors:
    Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System.
    Published Date:
    10/22/2020
    Series:
    National Notifiable Diseases: Infectious Weekly Tables 2020 week 42
    Description:
    2020-42-Table1w -H.pdf
    File Type:
    Filetype[PDF - 112.88 KB]
  2. Weekly cases of notifiable diseases, United States, U.S. territories, and Non-U.S. Residents weeks ending October 17, 2020 (Week 42) Table1x Meningococcal disease (continued)
    Corporate Authors:
    Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System.
    Published Date:
    10/22/2020
    Series:
    National Notifiable Diseases: Infectious Weekly Tables 2020 week 42
    Description:
    2020-42-Table1x -H.pdf
    File Type:
    Filetype[PDF - 99.08 KB]
  3. Weekly cases of notifiable diseases, United States, U.S. territories, and Non-U.S. Residents weeks ending October 10, 2020 (Week 41) Table1x Meningococcal disease (continued)
    Corporate Authors:
    Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System.
    Published Date:
    10/15/2020
    Series:
    National Notifiable Diseases: Infectious Weekly Tables 2020 week 41
    Description:
    2020-41-Table1x -H.pdf
    File Type:
    Filetype[PDF - 99.07 KB]
  4. Weekly cases of notifiable diseases, United States, U.S. territories, and Non-U.S. Residents weeks ending October 10, 2020 (Week 41) Table1w Meningococcal disease
    Corporate Authors:
    Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System.
    Published Date:
    10/15/2020
    Series:
    National Notifiable Diseases: Infectious Weekly Tables 2020 week 41
    Description:
    2020-41-Table1w -H.pdf
    File Type:
    Filetype[PDF - 112.85 KB]
  5. Role of the Advisory Committee on Immunization Practices in CDC’s vaccine recommendations
    Corporate Authors:
    National Center for Immunization and Respiratory Diseases (U.S.)
    Published Date:
    October 8, 2020
    Description:
    • The Centers for Disease Control and Prevention (CDC) sets the U.S. adult and childhood immunization schedules based on recommendations from the Advisory Committee on Immunization Practices (ACIP).• Before recommending any vaccine, ACIP consider...
    File Type:
    Filetype[PDF - 82.07 KB]